Search Results

Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.

As the biopharma industry grapples with the uncertain macro environment brought on by the new administration, CEOs, regulators and many others speak out.

Health and Human Services employees aren’t the only ones out of work. Thousands of private-sector biopharma professionals lost their jobs in the first quarter.

RedHill Biopharma Ltd. investors for the purchase and sale of 10,000,000 of the Company’s American Depositary Shares (“ADSs”) at a purchase price of $0.80 per ADS, in a registered direct offering.

Biopharma employees reporting a positive business outlook for their companies dropped month over month but increased year over year in February, according to the Glassdoor Employee Confidence Index. Glassdoor’s findings align with recent BioSpace data.

Over 80% of those living outside of biopharma’s biggest hubs, like San Diego or Boston, have a tough time finding work, according to a BioSpace LinkedIn poll. Biopharma professionals in Oregon and Connecticut and a BioSpace recruitment manager share their insights on this issue.

RedHill Biopharma Ltd. announced that it has closed its previously announced registered direct offering for the purchase and sale of 10,000,000 of the Company’s American Depositary Shares, each ADS representing four hundred ordinary shares, at a purchase price of $0.80 per ADS.

Nearly half of BioSpace poll respondents recently took a biopharma job they were overqualified for, a finding that didn’t surprise a talent acquisition expert, who said it’s become much more likely to happen.

RedHill Biopharma Ltd. announced that it has entered into definitive agreements with private investors for the purchase and sale, at a premium, of 2,144,487 of the Company’s American Depositary Shares, each ADS representing four hundred ordinary shares, par value NIS 0.01 per share, of the Company, and warrants to purchase up to an aggregate of 2,144,487ADSs, at a purchase price of $0.58289 per ADS and accompanying warrant, in a registered direct offering.

From ADCs and radiopharmaceuticals to cell and gene therapies, eager young startups are betting on advances in biopharma’s most competitive therapeutic spaces—and attracting dollars from Big Pharma.